HIV Cure: Antiretroviral Therapy-Free Control of HIV Infection
Apr 07–10, 2025 | Southern Sun Elangeni & Maharani, Durban, KZN, South Africa
Scientific Organizers:
Mike McCune, Thumbi Ndung'u, Sharon R Lewin, and Cissy Kityo
In Person
On Demand
×
-
Apr 07–10, 2025 | Southern Sun Elangeni & Maharani, Durban, KZN, South Africa
Scientific Organizers: Mike McCune, Thumbi Ndung'u, Sharon R Lewin, and Cissy Kityo
Mike McCune
Thumbi Ndung'u
Sharon R Lewin
Cissy Kityo
Available Formats:
Supported by:
In Person
On Demand
***Meeting program subject to change.
Available Formats: = In Person = On DemandMerchandise Options
Registration Options
Booking Function
Fundraising
Monday, April 7, 2025
Arrival and Registration
4:00–8:00 PM
Foyer
Welcome Mixer
6:00–8:00 PM
Foyer
Tuesday, April 8, 2025
Breakfast
7:30–8:30 AM
Individual Hotel
Poster Setup
8:00–8:30 AM
Suites 1-5
Poster Viewing
8:00–5:00 PM
Suites 1-5
Welcome and Keynote Address
8:30–9:30 AM
Great Ilanga
* Mike McCune, Gates Foundation
Thumbi Ndung'u, University of KwaZulu-Natal
Combination Approaches for HIV Cure in Resource-Limited Settings
Combination Approaches for HIV Cure in Resource-Limited Settings
Biology of the Rebound Competent Reservoir I: The how, what, and why of the HIV reservoir
9:30–11:45 AM
Great Ilanga
* Susana T. Valente, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation and Technology
Session Chair
Session Chair
Kavidha Reddy, Africa Health Research Institute (AHRI)
HIV-1 Reservoir Characteristics in Acutely Treated Adults and Children: Implications for HIV Cure Strategies
HIV-1 Reservoir Characteristics in Acutely Treated Adults and Children: Implications for HIV Cure Strategies
Ya-Chi Ho, Yale University
Mechanisms of HIV Persistence In Tissues - Single Cell Multi-Omic And Spatial Transcriptomic Approaches
Mechanisms of HIV Persistence In Tissues - Single Cell Multi-Omic And Spatial Transcriptomic Approaches
Sizun Jiang, Harvard
Technological Advancements for High-Dimensional Spatial Analysis of Tissue Viral Rebound Using an NHP SIV model
Technological Advancements for High-Dimensional Spatial Analysis of Tissue Viral Rebound Using an NHP SIV model
Isabella Ferreira, Weill Cornell Medicine
Short Talk: Propagation of Authentic HIV Reservoir Clones Reveals Functional Variability, Suggesting Diverse Mechanisms of Persistence
Short Talk: Propagation of Authentic HIV Reservoir Clones Reveals Functional Variability, Suggesting Diverse Mechanisms of Persistence
Alicer Andrew, Gladstone Institutes
Short Talk: CXCR5-expressing HIV-specific CD8+ T Cells from Elite Controllers Exhibit Signs of Recent but Not Chronic Activation
Short Talk: CXCR5-expressing HIV-specific CD8+ T Cells from Elite Controllers Exhibit Signs of Recent but Not Chronic Activation
Coffee Break
10:00–10:20 AM
Foyer
Lunch
11:45–12:45 PM
Suites 1-5
Poster Session 1
12:00–2:30 PM
Suites 1-5
Symposia Spotlight 1: Late-breaking research presentations selected from abstract submissions
2:30–4:30 PM
Great Ilanga
* Nonhlanhla N Mkhize, National Institute for Communicable Diseases
Session Chair
Session Chair
Helena Lamptey, Noguchi Memorial Institute for Medical Research, University of Ghana
The Impact of Hepatitis B Co-infection on T-Cell Responses and Reservoir Size in Virologically Suppressed HIV Patients on Antiretroviral Therapy in Ghana
The Impact of Hepatitis B Co-infection on T-Cell Responses and Reservoir Size in Virologically Suppressed HIV Patients on Antiretroviral Therapy in Ghana
Eric Arts, Western University
Packing the HLP Latency Reversal Agent with a Better Punch and Increasing Coverage as an HIV-1 Cure for all People Living with HIV
Packing the HLP Latency Reversal Agent with a Better Punch and Increasing Coverage as an HIV-1 Cure for all People Living with HIV
Christine Goffinet, Liverpool School of Tropical Medicine
Type I Interferons Sensitise HIV-1-reactivating T-cells for NK cell-mediated Elimination Despite HDACi-imposed Dysregulation of Innate Immunity
Type I Interferons Sensitise HIV-1-reactivating T-cells for NK cell-mediated Elimination Despite HDACi-imposed Dysregulation of Innate Immunity
Elena Martinelli, Northwestern University
Metabolic Reprogramming of CD4+ T Cells by TGF-β Inhibition and ART Shapes the SIV Reservoir
Metabolic Reprogramming of CD4+ T Cells by TGF-β Inhibition and ART Shapes the SIV Reservoir
Miguel Angel Marin Lopez, Africa Health Research Institute
Distinct CD4 Tissue-resident Memory (TRM) Depletion and CD8 TRM Function between the Small and Large Intestine Indicate Region-specific Mechanisms for Gut Pathology in People with HIV (PWH)
Distinct CD4 Tissue-resident Memory (TRM) Depletion and CD8 TRM Function between the Small and Large Intestine Indicate Region-specific Mechanisms for Gut Pathology in People with HIV (PWH)
Thuong D Nguyen, IRSICAIXA, Barcelona
ChAdOx1/MVA-based HTI Vaccination Induces Strong, Broad de-novo CD8 T Cell Responses of Elevated Functional Avidity
ChAdOx1/MVA-based HTI Vaccination Induces Strong, Broad de-novo CD8 T Cell Responses of Elevated Functional Avidity
Coffee Available
4:30–5:00 PM
Foyer
Biology of the Rebound Competent Reservoir II: Host Factors that influence HIV persistence
5:00–7:00 PM
Great Ilanga
* Glenda E Gray, HVTN / IDORI
Session Chair
Session Chair
Melanie M Ott, Gladstone Institutes
Silencing the Transcriptionally Active HIV Reservoir
Silencing the Transcriptionally Active HIV Reservoir
Sharon R Lewin, University of Melbourne
The Role of mRNA Therapeutics to Reverse HIV Latency
The Role of mRNA Therapeutics to Reverse HIV Latency
Caroline T. Tiemessen, National Institute for Communicable Diseases
Harnessing Immunogenetics in the Pursuit of Pediatric HIV Remission
Harnessing Immunogenetics in the Pursuit of Pediatric HIV Remission
Ujjwal Neogi, Karolinska Institutet
Mitochondrial Dysregulation and HIV Latency: A Metabolic Pathway to a Functional Cure?
Mitochondrial Dysregulation and HIV Latency: A Metabolic Pathway to a Functional Cure?
On Own for Dinner
7:00–8:00 PM
Wednesday, April 9, 2025
Breakfast
7:30–8:30 AM
Individual Hotel
Poster Setup
8:00–8:30 AM
Suites 1-5
Poster Viewing
8:00–5:00 PM
Suites 1-5
Sizing Up the Reservoir Using Molecular and Visual Tools
8:30–11:30 AM
Great Ilanga
* Mirko Paiardini, Emory University, ENPRC
Session Chair
Session Chair
Jake D Estes, Oregon Health and Science University
Decoding Tissue-Specific Dynamics of SIV Rebound in Nonhuman Primates
Decoding Tissue-Specific Dynamics of SIV Rebound in Nonhuman Primates
Zaza M. Ndhlovu, Africa Health Research Institute
Molecular Drivers of HIV-persistence and CD8+ T Cell Dysfunction in Human Lymphoid Tissues during ART-Suppressed Subtype C Infection
Molecular Drivers of HIV-persistence and CD8+ T Cell Dysfunction in Human Lymphoid Tissues during ART-Suppressed Subtype C Infection
Anna Farrell-Sherman, Fred Hutchinson Cancer Center
Circulating Non-Viral Biomarkers of the Rebound Competent Reservoir
Circulating Non-Viral Biomarkers of the Rebound Competent Reservoir
Thomas J. Hope, Northwestern University
Short Talk: Spatial Transcriptomics Reveals Persistent Reservoirs in the Rhesus Macaque Gut are Associated with Tertiary Lymphoid Organs and Stress Response Activation
Short Talk: Spatial Transcriptomics Reveals Persistent Reservoirs in the Rhesus Macaque Gut are Associated with Tertiary Lymphoid Organs and Stress Response Activation
Candace Liu, Stanford University
Short Talk: Multi-dimensional Longitudinal Spatial Profiling Reveals Dynamic ART-linked Lymphoid Tissue Remodeling in SIV Infection
Short Talk: Multi-dimensional Longitudinal Spatial Profiling Reveals Dynamic ART-linked Lymphoid Tissue Remodeling in SIV Infection
Marta Calvet-Mirabent, Gladstone Institutes
Short Talk: Active HIV Reservoir in Jejunum of ART-suppressed PWH Elicit Innate Immune Responses
Short Talk: Active HIV Reservoir in Jejunum of ART-suppressed PWH Elicit Innate Immune Responses
Faiaz Shaik Abdool, Africa Health Research Institute
Short Talk: Comparative Analysis of the HIV-1 Subclade C Reservoir Localization and Cellular Function in Pediatric and Adult Tonsillar Tissues
Short Talk: Comparative Analysis of the HIV-1 Subclade C Reservoir Localization and Cellular Function in Pediatric and Adult Tonsillar Tissues
Coffee Break
9:30–9:50 AM
Foyer
Award Recipient Acknowledgement
9:50–9:55 AM
Great Ilanga
Lunch
11:30–12:30 PM
Suites 1-5
Poster Session 2
12:00–2:30 PM
Suites 1-5
Career Roundtable
3:00–4:30 PM
Great Ilanga
Azwidihwi Nthangeni Takalani, HIV Vaccines Trial Network
Clinical Trial Physician (Protocol Team Leader)
Clinical Trial Physician (Protocol Team Leader)
Christine Goffinet, Liverpool School of Tropical Medicine
Professor
Professor
Megha L Mehrotra, Gilead Sciences
Associate Director of Clinical Development
Associate Director of Clinical Development
Evelyn Yayra A Bonney, Noguchi Memorial Institute for Medical Research, University of Ghana
Senior Research Fellow
Senior Research Fellow
Coffee Available
4:30–5:00 PM
Foyer
Therapeutic Approaches Leading to ART-Free Control of HIV I: What’s the magic ingredient?
5:00–7:00 PM
Great Ilanga
* Karsten Eichholz, Fred Hutchison Cancer Center
Session Chair
Session Chair
Thomas A Rasmussen, Aarhus University Hospital
Inhibiting the Anti-Apoptotic Factor, BCL-2, as an Approach to Targeting HIV Persistence
Inhibiting the Anti-Apoptotic Factor, BCL-2, as an Approach to Targeting HIV Persistence
Rachel L. Rutishauser, University of California, San Francisco
Eliciting Effective HIV-specific CD8+ T Cell Responses
Eliciting Effective HIV-specific CD8+ T Cell Responses
Ming Jie Lee, Imperial College London
The Use of Long-acting Broadly Neutralising Antibodies to Confer HIV Viral Control: Results from the RIO Study and Gut Sub-study
The Use of Long-acting Broadly Neutralising Antibodies to Confer HIV Viral Control: Results from the RIO Study and Gut Sub-study
Dylan M Postmus, Liverpool School of Tropical Medicine
Short Talk: Bryostatin-1, as Opposed to AZD5582, Impairs Cell Surface HIV-1 Env Presentation and Reduces Susceptibility to Immune Clearance during Synergistic HIV-1 Reactivation with JQ-1
Short Talk: Bryostatin-1, as Opposed to AZD5582, Impairs Cell Surface HIV-1 Env Presentation and Reduces Susceptibility to Immune Clearance during Synergistic HIV-1 Reactivation with JQ-1
Merle Henderson, Imperial College London/Imperial College Healthcare NHS Trust
Short Talk: The Impact of an HIV-broadly Neutralizing Antibody +/- Romidepsin at ART Start and during a Treatment Interruption on Biomarkers of Inflammation: The eCLEAR Study
Short Talk: The Impact of an HIV-broadly Neutralizing Antibody +/- Romidepsin at ART Start and during a Treatment Interruption on Biomarkers of Inflammation: The eCLEAR Study
On Own for Dinner
7:00–8:00 PM
Thursday, April 10, 2025
Breakfast
7:30–8:30 AM
Individual Hotel
Therapeutic Approaches Leading to ART-Free Control of HIV II: Might it all be in the genes?
8:30–11:30 AM
Great Ilanga
* Catherine K Koofhethile, Botswana Harvard Health Partnership
Session Chair
Session Chair
Cissy Kityo, Joint Clinical Research Centre
Anti-HIV CAR-T Cell Therapy
Anti-HIV CAR-T Cell Therapy
Mauricio Martins, University of Florida
AAV-Vectored Delivery of HIV Bnabs for Tackling Pediatric HIV Infection
AAV-Vectored Delivery of HIV Bnabs for Tackling Pediatric HIV Infection
Chang Li, University of Washington
In vivo HSC Gene Therapy of HIV/AIDS and SCD with Helper-Dependent Adenovirus Vectors
In vivo HSC Gene Therapy of HIV/AIDS and SCD with Helper-Dependent Adenovirus Vectors
James E. Voss, The Scripps Research Institute
Elicitation of Durable HIV bnAbs from Genome-edited B Cells as an Approach to Achieve a Functional Cure
Elicitation of Durable HIV bnAbs from Genome-edited B Cells as an Approach to Achieve a Functional Cure
Gerard Campos Gonzalez, IrsiCaixa
Short Talk: CAR-T Cells Targeting CD4 Efficiently Eliminate HIV-1 Infected T Cells
Short Talk: CAR-T Cells Targeting CD4 Efficiently Eliminate HIV-1 Infected T Cells
Michael Moso, University of Melbourne
Short Talk: CRISPR-activation for HIV Latency Reversal using Lipid Nanoparticle Delivery
Short Talk: CRISPR-activation for HIV Latency Reversal using Lipid Nanoparticle Delivery
Elena Herrera Carrillo, Amsterdam UMC
Short Talk: CRISPR-Cas Therapy Towards a Cure for HIV/AIDS
Short Talk: CRISPR-Cas Therapy Towards a Cure for HIV/AIDS
Coffee Break
9:30–9:50 AM
Foyer
Lunch
11:30–12:30 PM
Suites 1-5
Los Alamos HIV Immunology and Sequence Databases User Workshop
12:30–2:00 PM
Great Ilanga
Symposia Spotlight 2: Late-breaking research presentations selected from abstract submissions
2:30–4:30 PM
Great Ilanga
* Lishomwa C. Ndhlovu, Weill Cornell Medicine
Session Chair
Session Chair
Mirko Paiardini, Emory University, ENPRC
Immunological and Virological Characterization of Venetoclax-Induced Reservoir Reduction in SIV-Infected Rhesus Macaques
Immunological and Virological Characterization of Venetoclax-Induced Reservoir Reduction in SIV-Infected Rhesus Macaques
Henrik N Kløverpris, Africa Health Research Institute (AHRI)
Targeting Gut Inflammation in HIV with GLP-1 Therapy
Targeting Gut Inflammation in HIV with GLP-1 Therapy
Marisa Goff, Icahn School of Medicine at Mount Sinai
Combined Viral Outgrowth and Neutralization Assay to Quantify bNAb Sensitivity in the HIV-1 Latent Reservoir
Combined Viral Outgrowth and Neutralization Assay to Quantify bNAb Sensitivity in the HIV-1 Latent Reservoir
Panagiota Zacharopoulou, University of Oxford
Impact of bNAb Resistance-Associated Mutations on bNAb Treatment Outcomes in People with Early TreatedHIV in the RIO Trial
Impact of bNAb Resistance-Associated Mutations on bNAb Treatment Outcomes in People with Early TreatedHIV in the RIO Trial
Rose C Kitawi, University of New South Wales
Efficient Combinatorial Gene Therapy for Functional Cure of HIV Using miRshRNA Delivered RNA Sequences
Efficient Combinatorial Gene Therapy for Functional Cure of HIV Using miRshRNA Delivered RNA Sequences
Thembi Mdluli, Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF)
Initiating ART in Fiebig Stage I Limited the Development of Antibody Binding Responses Post ATI
Initiating ART in Fiebig Stage I Limited the Development of Antibody Binding Responses Post ATI
Coffee Available
4:30–5:00 PM
Foyer
Universal Access to Interventions that Lead to ART-Free Control of HIV: How are we going to make it happen?
5:00–6:45 PM
Great Ilanga
* Damalie Nakanjako, Makerere University College of Health Sciences
Session Chair
Session Chair
Steven G Deeks, University of California, San Francisco
Combination Approaches Towards Eradication or Control of HIV
Combination Approaches Towards Eradication or Control of HIV
Albert Machinda, The African HIV Cure Consortium (AHCC)
The African HIV Cure Consortium: Partnerships for Discovery, Development, and Roll Out of HIV Cure Initiatives in Africa
The African HIV Cure Consortium: Partnerships for Discovery, Development, and Roll Out of HIV Cure Initiatives in Africa
Patrick Mdletshe, University of KawZulu-Natal
Community Engagement for HIV Cure
Community Engagement for HIV Cure
Azwidihwi Nthangeni Takalani, HIV Vaccines Trial Network
Short Talk: Ensuring the Safe Implementation of Analytical Treatment Interruption in a Southern African Cohort
Short Talk: Ensuring the Safe Implementation of Analytical Treatment Interruption in a Southern African Cohort
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
6:45–7:00 PM
Great Ilanga
* Mike McCune, Gates Foundation
On Own for Dinner
7:00–8:00 PM
Friday, April 11, 2025
Departure
8:00–8:00 AM
Subscribe for Updates